SAB Biotherapeutics shares up 10.68% intraday on positive Phase 1 data for SAB-142 in Type 1 diabetes and $175M over-subscribed financing.

SAB Biotherapeutics surged 10.68% intraday, with the company announcing positive Phase 1 clinical trial data for SAB-142 showing early C-peptide preservation in type 1 diabetes patients, advancing the therapy to Phase 2b trials, and securing $175 million in over-subscribed financing. The company is a clinical-stage biopharmaceutical firm developing human anti-thymocyte IgA therapies for type 1 diabetes and other autoimmune diseases.